Cargando…

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study

BACKGROUND: Roxadustat has been shown effective in treating patients with anemia due to chronic kidney disease. However, its long-term effect on clinical outcomes and socioeconomic burden and safety remains unclear. METHODS/DESIGN: This is a multicenter, prospective, longitudinal observational cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yaling, Ren, Song, Xue, Hen, Wang, Amanda Y, Zou, Yang, Cai, Yanrong, He, Jingdong, Yuan, Xiaoling, Jiang, Feifei, Wei, Jinxi, Yang, Dongmei, He, Dong, Hu, Shide, Lei, Min, Deng, Fei, Chen, Jin, Wang, Xia, He, Qiang, Li, Guisen, Hong, Daqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805134/ https://www.ncbi.nlm.nih.gov/pubmed/33441103 http://dx.doi.org/10.1186/s12882-021-02229-w

Ejemplares similares

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study
por: Moussa, Oumarou, et al.
Publicado: (2022)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
por: Hirai, Keiji, et al.
Publicado: (2023)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
por: Zhang, Yangyang, et al.
Publicado: (2023)

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
por: Charytan, Chaim, et al.
Publicado: (2021)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Erythropoietin and iron for anemia in HIV-infected patients undergoing maintenance hemodialysis in China: a cross-sectional study
por: Peng, Lei, et al.
Publicado: (2022)

Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study
por: Jin, Chen, et al.
Publicado: (2022)

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2023)

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
por: Shutov, Evgeny, et al.
Publicado: (2021)

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623
por: Provenzano, Robert, et al.
Publicado: (2022)

The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2021)

Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
por: Zhang, Li, et al.
Publicado: (2021)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: Liu, Bo, et al.
Publicado: (2022)

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
por: Takada, Akitsugu, et al.
Publicado: (2021)

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
por: Akizawa, Tadao, et al.
Publicado: (2019)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
por: Xu, Cai, et al.
Publicado: (2022)

Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report
por: Zhou, Qiao-Qiao, et al.
Publicado: (2022)

The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials
por: Abdelazeem, Basel, et al.
Publicado: (2022)

Short-term effects of roxadustat on serum copper and iron changes in a peritoneal dialysis patient
por: Nakamura, Hironori, et al.
Publicado: (2022)

Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial
por: Zhang, Ping, et al.
Publicado: (2023)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
por: Ichii, Mitsuru, et al.
Publicado: (2021)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9iusrgggst2iv4ss2f4i3a2nkp